TY - JOUR T1 - <sup>111</sup>In-Pentetreotide SPECT/CT in Pulmonary Carcinoid JF - Anticancer Research JO - Anticancer Res SP - 4265 LP - 4270 VL - 35 IS - 7 AU - AGOSTINO CHIARAVALLOTI AU - ANGELA SPANU AU - ROBERTA DANIELI AU - FRANCESCA DORE AU - BASTIANA PIRAS AU - ANTONIO FALCHI AU - MARIO TAVOLOZZA AU - GIUSEPPE MADEDDU AU - ORAZIO SCHILLACI Y1 - 2015/07/01 UR - http://ar.iiarjournals.org/content/35/7/4265.abstract N2 - Aim: We evaluated somatostatin receptor scintigraphy (SRS) with 111In-pentetreotide incremental value in pulmonary carcinoid (PC) diagnosis compared to contrast enhanced Computed Tomography (ceCT). Patients and Methods: We enrolled 81 patients with ascertained PC, 39 at initial staging and 42 in follow-up; the primary tumor had already been excised in 68 cases. Single Photon emission Computed Tomography (SPECT) images were reconstructed with the iterative method and fused with non-enhanced Computed tomography (CT) images. Results: Primary PC or metastatic lesions were ascertained in 55/81 patients and SPECT/CT was positive in 50/55 cases, while ceCT was positive in 44/55. Comparing SPECT/CT with ceCT results, we found a sensitivity of 96 vs. 87.5%, and specificity of 92% vs. 97% for the detection of primary lesion or recurrent disease. A total of 198 lesions were ascertained at SPECT/CT, while 161 at ceCT, with values of sensitivity and specificity of 85.5% and 84.6% for SRS and 75.2% and 90.5% respectively. Conclusion: 111In-Pentetreotide SPECT/CT proved to be more sensitive and accurate than ceCT, thus enhancing its role in evaluating patients with PC. ER -